Drug profile · INN
exemestane
APO-EXEMESTANE
exemestane (APO-EXEMESTANE) is a cytochrome p450 19a1 inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — exemestane
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 25
- Data quality
- 0.89
Quick answer
exemestane (APO-EXEMESTANE) is a cytochrome p450 19a1 inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Reviewed by James Park Regulatory Affairs Editor Last reviewed Jun 8, 2026
Key facts
Mechanism of action
Cytochrome P450 19A1 inhibitor
Primary target: Aromatase
Approval history
Regional status spokes: FDA status · APAC status
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is exemestane?
exemestane (APO-EXEMESTANE) is a cytochrome p450 19a1 inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for exemestane?
APO-EXEMESTANE is a marketed brand name for exemestane. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of exemestane?
exemestane has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.